PD-L1 / CD-47 double-targeting protein degradation lysosome targeting chimera and application thereof in treatment of hepatic fibrosis

Through the lysosome-targeted chimera technology of PD-L1/CD-47 dual-targeted protein degradation, the problems of HSC activation and extracellular matrix synthesis in liver fibrosis treatment were solved, and the blockade of liver fibrosis and Reversal, significantly improving liver tissue damage.

CN118976114APending Publication Date: 2024-11-19HEBEI UNIV OF TECH

Patent Information

Application Number
CN202411061546.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-05
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing lysosomal targeting chimera techniques are not used to treat liver fibrosis, and there is a lack of methods to effectively inhibit activated hepatic stellate cells (HSCs) and reduce extracellular matrix synthesis.

Method used

A lysosome-targeted chimera with dual-targeted protein degradation of PD-L1/CD-47 was developed, and PD-L1 and CD-47 were transported to lysosomes for degradation and activation by targeting IGFIIR and RaRα receptors. T cells and macrophages kill HSCs, thereby blocking and reversing liver fibrosis.

Benefits of technology

By degrading PD-L1 and CD-47, activation and phagocytosis of HSCs are achieved, effectively reducing the pathological process of liver fibrosis, significantly improving liver tissue damage and reversing liver fibrosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976114A_ABST
    Figure CN118976114A_ABST
Patent Text Reader

Abstract

The invention discloses a PD-L1 / CD-47 double-targeting protein degraded lysosome targeting chimera and an application of the PD-L1 / CD-47 double-targeting protein degraded lysosome targeting chimera in treatment of hepatic fibrosis. According to the invention, PD-L1 and CD-47 are used as proteins to be degraded, and an aptamer targeting the PD-L1 and the CD-47 is connected with a retinoic acid small molecule targeting the IGFIIR and the RaR alpha, which is used as a lysosome targeting receptor, so that the lysosome targeting chimera for degrading the PD-L1 / CD-47 dual-targeting proteins is formed; according to the lysosome targeted chimera, target cell membrane proteins PD-L1 and CD-47 are transported into a lysosome through targeted receptors IGFIIR and RaR alpha for specific degradation, and the degraded PD-L1 and CD-47 can kill activated HSC through T cells and macrophages, so that the effect of blocking and reversing hepatic fibrosis is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to a lysosome-targeted chimera for dual-targeted protein degradation of PD-L1 / CD-47 and its application in the treatment of liver fibrosis. Background Art

[0002] Lysosome-targeting chimaeras (LYTAC) technology is a method that utilizes the endocytic-lysosomal pathway to degrade target proteins, mainly acting on membrane proteins and extracellular proteins that are resistant to proteasomes. Extracellular proteins and membrane-associated proteins are key factors in some important diseases, such as cancer, aging-related diseases, and autoimmune diseases. Therefore, targeted degradation of these proteins is of great significance to human health and has important research potential.

[0003] Liver fibrosis refers to a pathological process in which an imbalance in the synthesis and degradation of the extracellular matrix (ECM) leads to the abnormal accumulation of fibrous connective tissue in the liver. The occurrence and development of liver fibrosis is the result of the participation, interaction and mutual regulation of multiple cells, cytokines and signaling pathways. Activated hepatic stellate cells (HSC) migrate and proliferate in the damaged liver, express various signal transduction proteins, and produce a large amount of ECM and cytokines, which is the central link in the formation of liver fibrosis. Therefore, how to effectively inhibit HSC activation and proliferation and thus reduce ECM synthesis has become an important strategy for blocking and reversing liver fibrosis. There are currently no reports on the use of LYTAC technology to treat liver fibrosis.

[0004] In view of this, the present invention is proposed. Summary of the invention

[0005] The purpose of the present invention is to provide a lysosome-targeted chimera for dual-targeted protein degradation of PD-L1 / CD-47 and its application in the treatment of liver fibrosis. The PD-L1 / CD-47 dual-targeted lysosome-targeted chimera of the present invention can degrade PD-L1 and CD-47 on the surface of HSC, and then kill the activated HSC through T cells and macrophages, thereby achieving the effect of treating liver fibrosis.

[0006] The present invention is achieved in that:

[0007] In the first aspect, the present invention provides a lysosome-targeted chimera for dual-targeted protein degradation, wherein the lysosome-targeted chimera includes an aptamer for a lysosome-targeting receptor, an aptamer targeting a protein to be degraded, and a connection system connecting the aptamer for the lysosome-targeting receptor and the aptamer targeting the protein to be degraded; the aptamer for the lysosome-targeting receptor includes a retinoic acid small molecule targeting IGFIIR and RaRα; the proteins to be degraded include PD-L1 and CD-47.

[0008] In a second aspect, the present invention provides a pharmaceutical composition comprising the above-mentioned lysosome-targeted chimera for dual-targeted protein degradation, and at least one pharmaceutically acceptable excipient and / or carrier.

[0009] In a third aspect, the present invention provides the use of the above-mentioned lysosome-targeted chimera for dual-targeted protein degradation in the preparation of a drug for treating or assisting in the treatment of liver fibrosis.

[0010] In a fourth aspect, the present invention provides the use of the above-mentioned dual-targeted protein degradation lysosome-targeted chimera in the preparation of drugs for treating or assisting in the treatment of diseases related to the degradation of PD-L1 and CD-47.

[0011] In a fifth aspect, the present invention provides the use of the above-mentioned dual-targeted protein degradation lysosome targeting chimera in degrading PD-L1 and CD-47.

[0012] The present invention has the following beneficial effects:

[0013] The present invention takes PD-L1 and CD-47 as proteins to be degraded, and connects aptamers targeting PD-L1 and CD-47 with retinoic acid small molecules targeting IGFIIR and RaRα as lysosome targeting receptors, thereby forming a lysosome targeting chimera for PD-L1 / CD-47 dual-targeted protein degradation. The lysosome targeting chimera transports the target cell membrane proteins PD-L1 and CD-47 into lysosomes for specific degradation through the targeting receptors IGFIIR and RaRα, and the degradation of PD-L1 and CD-47 can kill activated HSCs through T cells and macrophages, thereby achieving the effect of blocking and reversing liver fibrosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0015] Figure 1 The lysosome-targeted chimera structure for dual-targeted protein degradation and the analysis results of its protein degradation ability in Example 3;

[0016] Figure 2 The lysosome-targeted chimera for dual-targeted protein degradation in Example 3 shows the change in PD-L1 protein expression level in HSC-T6 cells after being treated with 200 nM TdlTac-P3 chimera targeting membrane protein PD-L1 for 24 hours in the presence of 200 μM chloroquine (CQ);

[0017] Figure 3 Western analysis of the dual-targeted degradation ability of the lysosome-targeted chimera for dual-targeted protein degradation on cell membrane proteins in Example 3;

[0018] Figure 4 The distribution of each part of the lysosome targeting chimera in mice in Experimental Example 1 and the results of Sirius red staining of each group of materials after treating mice with liver fibrosis; A is the distribution of each part of the lysosome targeting chimera in mice; B is the results of Sirius red staining of each group of materials after treating mice with liver fibrosis;

[0019] Figure 5 The results of Sirius red staining and serum biochemistry after the treatment of liver fibrosis mice with the lysosome-targeted chimera for dual-targeted protein degradation in Experimental Example 2; A is the result of Sirius red staining; B is the result of serum biochemistry;

[0020] Figure 6 This is a western analysis of the dual-targeted degradation ability of lysosome-targeted chimeras for different dual-targeted protein degradation in Experimental Example 3 on cell membrane proteins. DETAILED DESCRIPTION

[0021] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0022] Based on the previous construction of lysosome targeting chimeras, the present invention selects specific lysosome targeting receptors and proteins to be degraded for liver fibrosis. The obtained new lysosome targeting chimeras have the characteristics of triple targeting and dual degradation, that is, simultaneously targeting IGFIIR, RaRα and specific biomacromolecules (PD-L1 and CD-47), and transporting PD-L1 and CD-47 to lysosomes through lysosome targeting receptors such as IGFIIR and RaRα for targeted degradation. The above-mentioned lysosome targeting chimeras can specifically regulate the physiological processes involved in PD-L1 and CD-47. Experiments have proved that the lysosome targeting chimeras can be used in the treatment of liver fibrosis.

[0023] The specific technical solutions are as follows:

[0024] An embodiment of the present invention provides a lysosome-targeted chimera for dual-targeted protein degradation, which includes an aptamer for a lysosome-targeted receptor, an aptamer targeting a protein to be degraded, and a connection system connecting the aptamer for the lysosome-targeted receptor and the aptamer targeting the protein to be degraded; the aptamer for the lysosome-targeted receptor includes a retinoic acid small molecule targeting IGFIIR and RaRα; the proteins to be degraded include PD-L1 and CD-47.

[0025] Retinoic acid is an intermediate product of vitamin A metabolism in the body, which mainly affects bone growth and promotes epithelial cell proliferation, differentiation, keratin dissolution and other metabolic effects. The present invention uses retinoic acid as an aptamer for the first time, and retinoic acid can target IGFIIR and RaRα receptors on the cell surface, especially hepatic stellate cells.

[0026] PD-L1 is a ligand of programmed death receptor 1 (PD1), belongs to the B7 superfamily, is a type I transmembrane protein, consists of 290 amino acids, and contains two IgV domains and an IgC domain in the extracellular region, which is connected to the intracellular region through a hydrophobic transmembrane region. It is mainly expressed on the surface of tumor-associated antigen presenting cells such as activated T lymphocytes, B lymphocytes, dendritic cells, macrophages, as well as on the surface of various tumor cells, various interstitial cells, vascular endothelial cells, heart, liver, placental tissue, etc. Since PD1 / PD-L1 is related to immune tolerance, and liver fibrosis is mainly caused by long-term damage to liver tissue by inflammation, PD-L1 is highly expressed during liver fibrosis. Therefore, the present invention uses PD-L1 as one of the proteins to be degraded. By degrading PD-L1, T cells can be promoted to kill activated HSCs, improve liver tissue damage, and thus reverse liver fibrosis.

[0027] CD-47 is a transmembrane protein encoded by the CD-47 gene in the human body and belongs to the immunoglobulin superfamily. Tumor cells highly express CD-47 and release the Don'teat me signal by binding to SIRPα on the surface of macrophages, thereby preventing tumor cells from being phagocytosed by macrophages. The present invention uses CD-47 as a protein to be degraded, and degrading CD-47 can promote macrophages to phagocytose activated hepatic stellate cells.

[0028] In some embodiments, the linking system includes biotin and avidin, and the aptamer for the lysosome targeting receptor and the aptamer for the protein to be degraded form a multi-target lysosome targeting chimera by binding biotin to avidin.

[0029] like Figure 1As shown in A, the connection system of the lysosome targeting chimera for dual-targeted protein degradation in the present invention adopts a biotin-avidin system, and each avidin can bind to 4 biotins. Therefore, the aptamer of the lysosome targeting receptor and the aptamer targeting the protein to be degraded can be selectively set in the lysosome targeting chimera. Specifically, the aptamer of the lysosome targeting receptor and the aptamer targeting the protein to be degraded can be 1:1, 1:2 or 1:3.

[0030] In some embodiments, biotin includes a first biotin, a second biotin, and a third biotin; the first biotin is connected to an aptamer of a lysosomal targeting receptor, and the second biotin and the third biotin are respectively connected to aptamers targeting a protein to be degraded. The aptamers targeting a protein to be degraded connected to the second biotin and the third biotin may be the same or different. In the present invention, the aptamer targeting a protein to be degraded connected to the second biotin is an aptamer targeting PD-L1, and the aptamer targeting a protein to be degraded connected to the third biotin is an aptamer targeting CD-47.

[0031] It should be noted that biotin can also include a fourth biotin, which can be connected to an aptamer targeting a lysosomal receptor, or can be connected to an aptamer targeting a protein to be degraded. Here, the aptamer targeting a protein to be degraded can be an aptamer targeting PD-L1 or an aptamer targeting CD-47, or can be an aptamer of any other protein to be degraded.

[0032] In some embodiments, the aptamer targeting the lysosomal receptor is linked to the first biotin via a linker, and the aptamer targeting the protein to be degraded is linked to the second biotin, the third biotin, and the fourth biotin via a linker.

[0033] In the present invention, the connection between the aptamer and biotin can be a conventional connection method in the art. In some embodiments, the linker includes any one or more of TEG and PEG.

[0034] In some embodiments, the molecular weight of PEG is 1k to 10k, and can specifically be any one of 1k, 2k, 3k, 4k, 5k, 6k, 7k, 8k, 9k and 10k, or a range between any two thereof.

[0035] In some embodiments, the aptamer targeted to the protein to be degraded comprises a polypeptide aptamer.

[0036] In some embodiments, the polypeptide aptamer includes a PD-L1 polypeptide and a CD-47 polypeptide, which targets PD-L1 and CD-47 on the surface of hepatic stellate cells and then transports them to lysosomes through lysosomal targeting receptors for targeted degradation.

[0037] In some embodiments, the molar ratio of the PD-L1 polypeptide to the CD-47 polypeptide in the dual-targeted protein degradation lysosome targeting chimera is 1-2:1-2.

[0038] The preparation method of the above-mentioned dual-targeted protein degradation lysosome targeting chimera provided by the present invention comprises: coupling a polypeptide aptamer targeting the protein to be degraded with biotin, then mixing the coupled products according to proportion, and then mixing them with retinoic acid small molecules and avidin to obtain a dual-targeted protein degradation lysosome targeting chimera.

[0039] Furthermore, the present invention also provides a pharmaceutical composition, which comprises the above-mentioned lysosome-targeted chimera for dual-targeted protein degradation, and at least one pharmaceutically acceptable excipient and / or carrier.

[0040] Furthermore, the present invention also provides the use of the above-mentioned lysosome-targeted chimera for dual-targeted protein degradation in the preparation of a drug for treating or assisting in the treatment of liver fibrosis.

[0041] Furthermore, the present invention also provides the use of the above-mentioned dual-targeted protein degradation lysosome targeting chimera in the preparation of drugs for treating or assisting in the treatment of diseases related to the degradation of PD-L1 and CD-47.

[0042] Furthermore, the present invention also provides the use of the above-mentioned dual-targeted protein degradation lysosome targeting chimera in degrading PD-L1 and CD-47.

[0043] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0044] Example 1

[0045] The present embodiment is a lysosome targeting chimera for dual-targeted protein degradation, and the lysosome targeting chimera includes: a lysosome targeting receptor, an aptamer targeting the protein to be degraded, and a connection system, wherein the connection system includes biotin and avidin, the lysosome targeting receptor is a retinoic acid small molecule targeting IGFIIR and RaRα, and the aptamer targeting the protein to be degraded is a polypeptide ligand targeting membrane protein: PD-L1 polypeptide, CD-47 polypeptide, and the N-terminus of the sequence thereof is connected to biotin through PEG (5k). The retinoic acid small molecule targeting IGFIIR and the aptamer targeting the protein to be degraded are coupled to form a lysosome targeting chimera through a biotin and avidin coupling system. For details, please refer to Figure 1 B.

[0046] Example 2

[0047] This example is a method for preparing the lysosome-targeted chimera for dual-targeted protein degradation of Example 1, and the specific steps are as follows:

[0048] (1) Retinoic acid small molecules targeting IGFⅡR coupled with biotin:

[0049] The retinoic acid small molecule targeting IGFⅡR is connected to the biotin of PEG-5k (Biotin-PEG(5k)-NH3) through its own carboxyl group and connected through an amide bond to synthesize a ligand targeting IGFⅡR and RaRα (V1, Biotin-PEG(5k)-VA).

[0050] (2) Method for coupling peptide aptamers targeting membrane proteins with biotin:

[0051] The peptide aptamers targeting membrane proteins (PD-L1 peptide and CD-47 peptide) were linked to biotin linked to PEG-5k (Biotin-PEG(5k)-COOH) through an amide bond via the amino group at the N-terminus to synthesize a peptide ligand targeting membrane protein (P1, Biotin-PEG(5k)-peptide).

[0052] (3) The preparation method of the lysosome-targeted chimera for dual-targeted protein degradation comprises:

[0053] The peptide aptamers targeting different membrane proteins were mixed in different molar ratios (PD-L1 peptide (P) and CD-47 peptide (C) were mixed in ratios of 3:0, 2:1, 1:2, and 0:3, respectively; PD-L1 peptide (P) and CD-47 peptide (C) were mixed in ratios of 3:0, 2:1, 1:2, and 0:3, respectively). Then, a mixture of retinoic acid small molecules targeting the lysosomal receptor IGFⅡR and peptide aptamers targeting membrane proteins were mixed with avidin in a molar ratio of 1:3:1, and connected through an avidin-biotin system to synthesize a multi-component lysosomal targeting chimera.

[0054] Example 3

[0055] This example is a verification of the degradation ability of the lysosome-targeted chimera for dual-targeted protein degradation prepared in Example 2 on PD-L1 and CD-47, as follows:

[0056] 1. Effects of different dual-targeted protein degradation lysosome-targeted chimeras on the degradation ability of PD-L1 and CD-47

[0057] S1. Digest the HSC-T6 cells cultured in a T25 culture flask with trypsin, place in a 15 ml centrifuge tube, centrifuge at 1000 rpm for 5 min, discard the supernatant, resuspend the cell pellet in DMEM high-glucose medium containing 10% fetal bovine serum and 1% penicillin-streptomycin, take 20 μL of the cell suspension and count. Take an appropriate amount of the cell suspension and spread it into a 6-well plate, 2*10 cells per well. 6 Gently shake the well plate in a "cross" pattern to evenly distribute the cells in the well plate and place it at 37°C with 5% CO.2 The cells were cultured in the incubator for 24 hours. After 24 hours, the cells adhered to the wall and the drug was started.

[0058] S2. Prepare a system with a concentration of 500μM. Take two 0.5ml centrifuge tubes. Add 25μL of retinoic acid small molecules with biotin 1 at a concentration of 20μM to each centrifuge tube, add 75μL of PD-L1 small peptide with biotin 2 at a concentration of 20μM, vortex mix, place at room temperature for 5min, add 25μL s-avidin, vortex mix immediately, and place at room temperature for 30min. Take one of the 500μM systems and dilute it to 250μM, 125μM, 62.5μM, and 31.25μM with culture medium without serum and double antibodies. The total volume of each concentration is 1ml. Add 875μL of culture medium without serum and double antibodies to the other 500μM system to a total volume of 1ml. Discard the culture medium in the well plate, rinse it with PBS, discard PBS, add the gradient system in turn, and directly add 1ml of culture medium without serum and double antibodies to the control group. Gently shake the well plate to evenly distribute the culture medium. Place in an incubator at 37°C and 5% CO 2 After 10 hours, 1 ml of DMEM high-glucose medium containing 10% FBS and 1% double antibody was added to each well. After 24 hours, the cells were collected and cell proteins were extracted.

[0059] S3. Discard the culture medium in the well plate, rinse with pre-cooled PBS, discard PBS, dissociate the cells from the bottom of the well plate with a cell scraper or a cell dissociation solution containing EDTA but not trypsin, collect the cells into a 1.5ml centrifuge tube, collect the cells at 8000rpm for 2min, gently pour out the supernatant, 8000rpm for 30sec, gently aspirate the remaining supernatant with a 200μL pipette, add cell lysis solution (RIPA:PMSF=100:1) according to the amount of cells, vortex the cell pellet, place it on ice for lysis, vortex once every ten minutes, for a total of 3 times. Centrifuge at 12000rpm for 10min. Prepare the working solution, A solution: B solution=50:1, take another 6 1.5ml centrifuge tubes, add 27μL water, 600μL working solution, 3μL supernatant after centrifugation to each centrifuge tube, vortex evenly, and place in a 37℃ oven for 30min. Take a clean 96-well plate, take 180 μL of each sample and add it to the 96-well plate. Repeat three times for each sample, measure the absorbance at a wavelength of 562 nm, and substitute the absorbance into the standard curve prepared in advance to calculate the concentration and loading volume. After centrifugation, place the remaining supernatant in another 1.5 ml centrifuge tube, add 5x protein loading buffer according to the volume of the supernatant, vortex to mix, and place in a 100 ° C metal bath for 10 minutes. Then perform protein electrophoresis.

[0060] S4. Prepare separation gel and stacking gel, load samples, perform electrophoresis, transfer to membrane, block, incubate primary and secondary antibodies, and expose bands. At this point, the experiment is complete.

[0061] 2. Effects of different treatment times on the degradation ability of PD-L1 and CD-47

[0062] S1. Digest the HSC-T6 cells cultured in a T25 culture flask with trypsin, place them in a 15 ml centrifuge tube, centrifuge at 1000 rpm for 5 min, discard the supernatant, resuspend the cell pellet in DMEM high-glucose medium containing 10% fetal bovine serum and 1% penicillin-streptomycin, and take 20 μL of the cell suspension for counting. Take an appropriate amount of the cell suspension and spread it into a 6-well plate, 2*10 cells per well. 6 Gently shake the well plate in a "cross" pattern to evenly distribute the cells in the well plate and place it at 37°C with 5% CO. 2 The cells were cultured in the incubator for 24 hours. After 24 hours, the cells adhered to the wall and the drug was started.

[0063] S2. Take 4 0.5ml centrifuge tubes, add 10μL of retinoic acid small molecules linked to biotin 1 at a concentration of 20μM to each centrifuge tube, add 30μL of PD-L1 small peptide linked to biotin 2 at a concentration of 20μM, vortex to mix, leave at room temperature for 5min, add 10μL s-avidin, vortex to mix immediately, and leave at room temperature for 30min. Add culture medium without serum and double antibodies to each centrifuge tube to a total volume of 1ml. Discard the culture medium in the well plate, rinse with PBS, discard PBS, add the drug system in turn, directly add 1ml of culture medium without serum and double antibodies to the control group, and gently shake the well plate to evenly distribute the culture medium. Culture in an incubator at 37°C and 5% CO 2,10h later, add 1ml of DMEM high-glucose medium containing 10% FBS and 1% double antibody to each well. 24h later, collect cells and extract cell proteins. Discard the medium in the well plate, rinse with pre-cooled PBS, discard PBS, dissociate cells from the bottom of the well plate with a cell scraper or a cell dissociation solution containing EDTA but not trypsin, collect cells into a 1.5ml centrifuge tube, collect cells at 8000rpm for 2min, gently pour out the supernatant, 8000rpm for 30sec, gently aspirate the remaining supernatant with a 200μL pipette, add cell lysis solution (RIPA:PMSF=100:1) according to the amount of cells, vortex the cell pellet, place it on ice for lysis, vortex once every ten minutes, for a total of 3 times. Centrifuge at 12000rpm for 10min. Prepare working solution, A solution: B solution = 50:1, take another 4 1.5ml centrifuge tubes, add 27μL water, 600μL working solution, 3μL supernatant after centrifugation to each centrifuge tube, vortex evenly, and place in a 37℃ oven for 30min. Take a clean 96-well plate, take 180μL of each sample and add it to the 96-well plate, repeat three times for each sample, measure the absorbance at a wavelength of 562nm, and substitute the absorbance into the standard curve prepared in advance to calculate the concentration and sample volume. After centrifugation, place the remaining supernatant in another 1.5ml centrifuge tube, add 5x protein loading buffer according to the supernatant volume, vortex to mix, and place in a 100℃ metal bath for 10min. Then perform protein electrophoresis.

[0064] S3. Prepare separation gel and stacking gel, load samples, perform electrophoresis, transfer to membrane, block, incubate primary and secondary antibodies, and expose bands. At this point, the experiment is complete.

[0065] Figure 1 The structure of the dual-target lysosomal targeting chimera and its protein degradation ability analysis are shown; wherein A is a schematic diagram of the structure of the multi-component targeting chimera, P represents the polypeptide ligand of the membrane protein targeting receptor, V represents the retinoic acid small molecule that can be targeted and connected to IGFIIR and RaRα, and the intermediate linker is connected using PEG; B is a schematic diagram of the V1P3 dual-target lysosomal targeting chimera Tretinoin derived lysosomal targeting chimeras (abbreviated as TdlTac) synthesized by combining the small molecule linked to retinoic acid and the polypeptide aptamer targeting membrane protein in a 1:3 ratio based on the presence of four biotin sites in avidin.

[0066] Figure 1 C is the concentration gradient effect of TdlTac-P3 on the level of PD-L1 protein in the hepatic stellate cell line HSC-T6 membrane protein. It can be concluded that with the increase of TdlTac-P3 concentration, the degradation degree of the protein to be degraded PD-L1 increases; Figure 1D is the time gradient effect of TdlTac-P3 on the protein level of PD-L1 membrane protein in the hepatic stellate cell line HSC-T6. It can be concluded that TdlTac-P3 maintains its structural integrity within 24 hours and continuously degrades the protein to be degraded PD-L1.

[0067] 3. Effect of lysosome-targeted chimeras for dual protein degradation on PD-L1 protein expression levels in the presence of chloroquine

[0068] S1. Digest the HSC-T6 cells cultured in a T25 culture flask with trypsin, place in a 15 ml centrifuge tube, centrifuge at 1000 rpm for 5 min, discard the supernatant, resuspend the cell pellet in DMEM high-glucose medium containing 10% fetal bovine serum and 1% penicillin-streptomycin, take 20 μL of the cell suspension and count. Take an appropriate amount of the cell suspension and spread it into a 6-well plate, 2*10 cells per well. 6 Gently shake the well plate in a "cross" pattern to evenly distribute the cells in the well plate and place it at 37°C with 5% CO. 2 The cells were cultured in the incubator for 24 hours. After 24 hours, the cells adhered to the wall and the drug was started.

[0069] S2. Take 2 1.5ml centrifuge tubes and add 1ml of medium without serum and double antibody, add CQ to make the final concentration of CQ 20μM, mix evenly, add to CQ group and CQ+TdlTac-P3 group respectively, and gently shake the plate to evenly distribute the medium. 2h later, take 3 0.5ml centrifuge tubes, add 10μL of retinoic acid small molecule with biotin 1 at a concentration of 20μM to each centrifuge tube, add 30μL of PD-L1 small peptide with biotin 2 at a concentration of 20μM, vortex mix, place at room temperature for 5min, add 10μL s-avidin, vortex mix immediately, and place at room temperature for 30min. Add medium without serum and double antibody to each centrifuge tube to a total volume of 1ml. Discard the medium in the plate, rinse with PBS, discard PBS, add the drug system in turn, and directly add 1ml of medium without serum and double antibody to the control group, and gently shake the plate to evenly distribute the medium. Place in an incubator at 37°C and 5% CO 2 ,10h later, 1 ml of DMEM high-glucose medium containing 10% FBS and 1% double antibody was added to each well. 24h later, cells were collected and cell proteins were extracted.

[0070] S3. Discard the culture medium in the well plate, rinse with pre-cooled PBS, discard PBS, dissociate the cells from the bottom of the well plate with a cell scraper or a cell dissociation solution containing EDTA but not trypsin, collect the cells into a 1.5ml centrifuge tube, collect the cells at 8000rpm for 2min, gently pour out the supernatant, 8000rpm for 30sec, gently aspirate the remaining supernatant with a 200μL pipette, add cell lysis solution (RIPA:PMSF=100:1) according to the amount of cells, vortex the cell pellet, place it on ice for lysis, vortex once every ten minutes, for a total of 3 times. Centrifuge at 12000rpm for 10min. Prepare the working solution, A solution: B solution=50:1, take another 6 1.5ml centrifuge tubes, add 27μL water, 600μL working solution, 3μL supernatant after centrifugation to each centrifuge tube, vortex evenly, and place in a 37℃ oven for 30min. Take a clean 96-well plate, take 180 μL of each sample and add it to the 96-well plate. Repeat three times for each sample, measure the absorbance at a wavelength of 562 nm, and substitute the absorbance into the standard curve prepared in advance to calculate the concentration and loading volume. After centrifugation, place the remaining supernatant in another 1.5 ml centrifuge tube, add 5x protein loading buffer according to the volume of the supernatant, vortex to mix, and place in a 100 ° C metal bath for 10 minutes. Then perform protein electrophoresis.

[0071] S4. Prepare separation gel and stacking gel, load samples, perform electrophoresis, transfer to membrane, block, incubate primary and secondary antibodies, and expose bands. At this point, the experiment is complete.

[0072] Figure 2 Shown is the change in PD-L1 protein expression level in HSC-T6 cells treated with 200 nM TdlTac-P3 chimera targeting membrane protein PD-L1 in the presence of 200 μM chloroquine (CQ) for 24 hours.

[0073] according to Figure 2 The experimental results show that TdlTac-P3 degrades protein through the lysosomal pathway.

[0074] 4. Western analysis of the dual-targeted degradation ability of lysosome-targeted chimeras for cell membrane proteins

[0075] S1. Digest the HSC-T6 cells cultured in a T25 culture flask with trypsin, place in a 15 ml centrifuge tube, centrifuge at 1000 rpm for 5 min, discard the supernatant, resuspend the cell pellet in DMEM high-glucose medium containing 10% fetal bovine serum and 1% penicillin-streptomycin, take 20 μL of the cell suspension and count. Take an appropriate amount of the cell suspension and spread it into a 6-well plate, 2*10 cells per well. 6 Gently shake the well plate in a "cross" pattern to evenly distribute the cells in the well plate and place it at 37°C with 5% CO. 2The cells were cultured in the incubator for 24 hours. After 24 hours, the cells adhered to the wall and the drug was started.

[0076] S2. Take 4 0.5ml centrifuge tubes, add 10μL of retinoic acid small molecules connected with biotin 1 at a concentration of 20μM to each centrifuge tube, add 30μL, 20μL, 10μL, 0μL of PD-L1 small peptide connected with biotin 2 at a concentration of 20μM, 0μL, 10μL, 20μL, 30μL of CD-47 small peptide connected with biotin 3, vortex mix, place at room temperature for 5min, add 10μL s-avidin, vortex mix immediately, and place at room temperature for 30min. Add culture medium without serum and double antibody to each centrifuge tube to a total volume of 1ml. Discard the culture medium in the well plate, rinse with PBS, discard PBS, add the drug system in turn, directly add 1ml of culture medium without serum and double antibody to the control group, and gently shake the well plate to evenly distribute the culture medium. Culture in an incubator at 37℃, 5% CO 2 After 10 hours, 1 ml of DMEM high-glucose medium containing 10% FBS and 1% double antibody was added to each well. After 24 hours, the cells were collected and cell proteins were extracted.

[0077] S3. Discard the culture medium in the well plate, rinse with pre-cooled PBS, discard PBS, dissociate the cells from the bottom of the well plate with a cell scraper or a cell dissociation solution containing EDTA but not trypsin, collect the cells into a 1.5ml centrifuge tube, collect the cells at 8000rpm for 2min, gently pour out the supernatant, 8000rpm for 30sec, gently aspirate the remaining supernatant with a 200μL pipette, add cell lysis solution (RIPA:PMSF=100:1) according to the amount of cells, vortex the cell pellet, place it on ice for lysis, vortex once every ten minutes, for a total of 3 times. Centrifuge at 12000rpm for 10min. Prepare the working solution, A solution: B solution=50:1, take another 4 1.5ml centrifuge tubes, add 27μL water, 600μL working solution, 3μL supernatant after centrifugation to each centrifuge tube, vortex evenly, and place in a 37℃ oven for 30min. Take a clean 96-well plate, take 180 μL of each sample and add it to the 96-well plate. Repeat three times for each sample, measure the absorbance at a wavelength of 562 nm, and substitute the absorbance into the standard curve prepared in advance to calculate the concentration and loading volume. After centrifugation, place the remaining supernatant in another 1.5 ml centrifuge tube, add 5x protein loading buffer according to the volume of the supernatant, vortex to mix, and place in a 100 ° C metal bath for 10 minutes. Then perform protein electrophoresis.

[0078] S4. Prepare separation gel and stacking gel, load samples, perform electrophoresis, transfer to membrane, block, incubate primary and secondary antibodies, and expose bands. At this point, the experiment is complete.

[0079] Figure 3The figure shows the western analysis of the dual-targeted degradation ability of the lysosome-targeted chimera for dual-targeted protein degradation on cell membrane proteins; wherein, A shows the structural schematic diagram of the multi-component degradation of cell membrane proteins by the lysosome-targeted chimera TdlTac for dual-targeted protein degradation; B shows the changes in the degradation levels of different component ratios of cell membrane proteins PD-L1 and CD-47 by the TdlTac chimera, wherein different L3 chimeras (V1P3, V1P2C1, M1P1C2, M1C3) are formed by the ratios of 3:0, 2:1, 1:2, and 0:3 of membrane protein PD-L1 and CD-47 polypeptide.

[0080] according to Figure 3 The experimental results show that the lysosome targeting chimera can simultaneously achieve the degradation of the dual proteins PD-L1 and CD-47.

[0081] Experimental Example 1

[0082] This experiment is to investigate the distribution of each part of the lysosome-targeted chimera in mice and the therapeutic effects of each group of materials on mice with liver fibrosis.

[0083] (1) One month in advance, C57, 6-week-old male mice were induced to develop liver fibrosis. A system containing 20% ​​carbon tetrachloride (CCL4: olive oil = 1:4) was injected every Monday, Wednesday, and Friday, with an induction dose of 2 μL / g. Taking the amount of drug injected per mouse as an example, a 1.5 ml centrifuge tube was taken, 25 μL of retinoic acid small molecules linked to biotin 1, a small peptide of PD-L1 linked to biotin 2, and 25 μL of 50 μL Cy5 fluorescent group linked to biotin 1 were added, vortexed and mixed, and placed at room temperature for 5 minutes. 25 μL of s-avidin was added and mixed immediately, and placed at room temperature for 30 minutes. The mice were injected into the tail vein, and the mice were dissected 6 hours later to collect the heart, liver, spleen, lung, and kidney. The images were taken using a small animal imaging instrument.

[0084] (2) Experimental animals were six-week-old C57 male mice. 20% carbon tetrachloride (CCL4: olive oil = 1:4) was intraperitoneally injected into the mice every Monday, Wednesday, and Friday to induce liver fibrosis for 12 times in total. Meanwhile, medication was given every Tuesday, Thursday, and Saturday. Normal refers to normal C57 male mice; CCL4 group only induced liver fibrosis without treatment; different concentrations of small peptide groups are to dissolve the synthesized peptides with DMSO into a mother solution with a concentration of 10mM, and then dilute with normal saline; TdlTac-P3 / C3 group is to dilute the retinoic acid small molecule linked to biotin 1, the small peptides of PD-L1 and CD-47 linked to biotin 2 and biotin 3, and streptavidin into a working solution with a mother solution of 150μM. Taking the dosage of one mouse as an example, take a 1.5ml centrifuge tube, add 40μL of retinoic acid small molecule linked to biotin 1, 120μL of small peptides of PD-L1 and CD-47 linked to biotin 2 and biotin 3, vortex mix, leave at room temperature for 5min, then add 40μL of s-avidin, mix immediately, and leave at room temperature for 30min. Intraperitoneal injection. 24 hours after the 12th administration, the mice were killed by dislocation, and the livers were removed, fixed with paraformaldehyde, and sent to the company for picrosirius red staining.

[0085] Figure 4 The results of picrosirius red staining were shown in C57 mice after inducing liver fibrosis and then injecting the complete TdlTac labeled with Cy5 fluorescence and the various components that make up the lysosome targeting chimera into their tail veins; and the results of picrosirius red staining were shown in mice with liver fibrosis after treatment with small peptides of individual proteins to be degraded and TdlTac-P3, respectively.

[0086] according to Figure 4 Results A show that the fluorescence intensity of the complete lysosome-targeted chimera in the liver is significantly higher than that of the individual components, further indicating that the complete lysosome-targeted chimera stays longer in the liver of mice with liver fibrosis and has a better therapeutic effect. Figure 4 B Result shows that the same concentration of TdlTac-P3 has a better therapeutic effect on liver fibrosis than the PD-L1 peptide alone, which is almost equivalent to 10 times the concentration of the peptide alone.

[0087] Experimental Example 2

[0088] This study is to identify the dual-targeted protein degradation lysosome-targeted chimera for the treatment of liver fibrosis in mice

[0089] The experimental animals were six-week-old C57 male mice. 20% carbon tetrachloride (CCL4: olive oil = 1:4) was injected intraperitoneally on Mondays, Wednesdays, and Fridays to induce liver fibrosis for a total of 12 times. Meanwhile, medication was given on Tuesdays, Thursdays, and Saturdays. Normal refers to normal C57 male mice; CCL 4The TdlTac-P group was only treated with liver fibrosis induction without treatment. 2 C 1 / P 1 C 2 The retinoic acid small molecule linked to biotin 1, the small peptides of PD-L1 and CD-47 linked to biotin 2 and biotin 3, and streptavidin were diluted into a working solution with a mother solution of 150 μM. Taking the dosage for one mouse as an example, a 1.5 ml centrifuge tube was taken, and 40 μL of the retinoic acid small molecule linked to biotin 1, 80 μL of the small peptides of PD-L1 and CD-47 linked to biotin 2 and 40 μL of the small peptides of PD-L1 and CD-47 linked to biotin 3 (TdlTac-P 2 C 1 ), 40 μL of retinoic acid small molecules linked to biotin 1, 40 μL of PD-L1 and CD-47 small peptides linked to biotin 2 and 80 μL of biotin 3 (TdlTac-P 1 C 2 ) vortex to mix, place at room temperature for 5 minutes, then add 40μL s-avidin, mix immediately, and place at room temperature for 30 minutes. Intraperitoneal injection. 24 hours after the 12th administration, remove the eyeball to collect blood, collect the blood in an anticoagulant tube, place on ice for 30 minutes, and then 3000rpm for 10 minutes to collect the supernatant as serum, which is sent to the company for biochemical testing; remove the liver, fix it with paraformaldehyde, and send it to the company for Sirius red staining.

[0090] Figure 5 The results of Sirius red staining after the treatment of liver fibrosis mice with dual-targeted (i.e., PD-L1 and CD-47) lysosome targeting chimeras; and the serum biochemical results after the treatment of liver fibrosis mice with dual-targeted lysosome targeting chimeras.

[0091] according to Figure 5 A result shows that the dual-targeted protein degradation lysosome-targeted chimera has a therapeutic effect on mouse liver fibrosis, and according to the picrosirius red result, it can be concluded that the best effect is achieved when the ratio of the PD-L1 small peptide to the CD-47 small peptide in the targeting chimera is 2:1; according to Figure 5 Result B shows that the lysosome-targeted chimera pair with dual targeted protein degradation can reverse ALT / AST in the blood of mice with liver fibrosis.

[0092] Experimental Example 3

[0093] In this experiment, the nucleic acid aptamer targeting IGFIIR recorded in Example 1 of CN 117122690 A replaced the retinoic acid small molecule in Example 1 of the present invention to prepare a control dual-targeted protein degradation lysosome targeting chimera, and compared it with the dual-targeted protein degradation lysosome targeting chimera in Example 1 of the present invention, as follows:

[0094] S1. Digest the HSC-T6 cells cultured in a T25 culture flask with trypsin, place in a 15 ml centrifuge tube, centrifuge at 1000 rpm for 5 min, discard the supernatant, resuspend the cell pellet in DMEM high-glucose medium containing 10% fetal bovine serum and 1% penicillin-streptomycin, take 20 μL of the cell suspension and count. Take an appropriate amount of the cell suspension and spread it into a 6-well plate, 2*10 cells per well. 6 Gently shake the well plate in a "cross" pattern to evenly distribute the cells in the well plate and place it at 37°C with 5% CO. 2 The cells were cultured in the incubator for 24 hours. After 24 hours, the cells adhered to the wall and the drug was started.

[0095] S2. Take two 0.5 ml centrifuge tubes, add 10 μL of 20 μM retinoic acid small molecule linked to biotin 1 to one centrifuge tube, add 20 μM IGF2R nucleic acid aptamer to the other, and add 30 μL of 20 μM PD-L1 small peptide linked to biotin 2 to both tubes. Figure 6 A), add 30 μL of 20 μM CD-47 peptide linked to biotin 3 ( Figure 6 B) Vortex to mix, place at room temperature for 5 minutes, add 10μL s-avidin, vortex to mix immediately, and place at room temperature for 30 minutes. Add serum-free and dual-antibody culture medium to each centrifuge tube to a total volume of 1ml. Discard the culture medium in the well plate, rinse with PBS, discard PBS, add the drug system in turn, directly add 1ml serum-free and dual-antibody culture medium to the control group, and gently shake the well plate to evenly distribute the culture medium. Place in an incubator for culture at 37°C, 5% CO 2, 10h later, add 1ml of DMEM high-glucose medium containing 10% FBS and 1% double antibody to each well. After 24h, collect cells and extract cell protein. Discard the medium in the well plate, rinse with pre-cooled PBS, discard PBS, dissociate cells from the bottom of the well plate with a cell scraper or a cell dissociation solution containing EDTA but not trypsin, collect cells into a 1.5ml centrifuge tube, collect cells at 8000rpm for 2min, gently pour out the supernatant, 8000rpm for 30sec, use a 200μL pipette to gently remove the remaining supernatant, add cell lysis solution (RIPA:PMSF=100:1) according to the amount of cells, vortex the cell pellet, place it on ice for lysis, vortex once every ten minutes, for a total of 3 times. Centrifuge at 12000rpm for 10min. Prepare working solution, A solution: B solution = 50:1, take another 6 1.5ml centrifuge tubes, add 27μL water, 600μL working solution, 3μL supernatant after centrifugation to each centrifuge tube, vortex evenly, and place in a 37℃ oven for 30min. Take a clean 96-well plate, take 180μL of each sample and add it to the 96-well plate, repeat three times for each sample, measure the absorbance at a wavelength of 562nm, and substitute the absorbance into the standard curve prepared in advance to calculate the concentration and sample volume. After centrifugation, place the remaining supernatant in another 1.5ml centrifuge tube, add 5x protein loading buffer according to the supernatant volume, vortex to mix, and place in a 100℃ metal bath for 10min. Then perform protein electrophoresis.

[0096] S3. Prepare separation gel and stacking gel, load samples, perform electrophoresis, transfer to membrane, block, incubate primary and secondary antibodies, and expose bands. At this point, the experiment is complete.

[0097] from Figure 6 It can be seen that compared with the nucleic acid aptamer targeting IGFIIR described in Example 1 of CN 117122690 A, the retinoic acid small molecule used in the present invention has a better effect in degrading PD-L1 and CD-47.

[0098] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A lysosome-targeted chimera for dual-targeted protein degradation, characterized in that: The lysosome targeting chimera includes an aptamer of a lysosome targeting receptor, an aptamer targeting a protein to be degraded, and a connection system connecting the aptamer of the lysosome targeting receptor and the aptamer targeting the protein to be degraded; The aptamer of the lysosome targeting receptor includes a retinoic acid small molecule targeting IGFIIR and RaRα; the proteins to be degraded include PD-L1 and CD-47.

2. The lysosomal targeting chimera according to claim 1, characterized in that The connection system includes biotin and avidin, and the aptamer of the lysosome targeting receptor and the aptamer targeting the protein to be degraded form the lysosome targeting chimera through biotin binding to avidin; Preferably, the biotin includes a first biotin, a second biotin and a third biotin; the first biotin is connected to the aptamer of the lysosomal targeting receptor, and the second biotin and the third biotin are respectively connected to the aptamer targeting the protein to be degraded.

3. The lysosomal targeting chimera according to claim 2, characterized in that The aptamer targeting the lysosome receptor is connected to the first biotin via a linker, and the aptamer targeting the protein to be degraded is connected to the second biotin and the third biotin via a linker; Preferably, the linker comprises any one or more of TEG and PEG; Preferably, the molecular weight of the PEG is 1k-10k.

4. The lysosomal targeting chimera according to claim 3, characterized in that The aptamer targeting the protein to be degraded includes a polypeptide aptamer; Preferably, the polypeptide aptamer comprises PD-L1 polypeptide and CD-47 polypeptide.

5. The lysosomal targeting chimera according to claim 4, characterized in that The molar ratio of the PD-L1 polypeptide to the CD-47 polypeptide in the lysosome targeting chimera is 1-2:1-2.

6. The lysosomal targeting chimera according to claim 5, characterized in that The preparation method of the lysosome targeting chimera comprises: coupling the polypeptide aptamer targeting the protein to be degraded with biotin, then mixing the coupled products in proportion, and then mixing them with retinoic acid small molecules and avidin to obtain the lysosome targeting chimera.

7. A pharmaceutical composition, characterized in that It comprises the lysosome targeting chimera for dual-targeted protein degradation according to any one of claims 1 to 6, and at least one pharmaceutically acceptable excipient and / or carrier.

8. Use of the lysosome-targeted chimera for dual-targeted protein degradation according to any one of claims 1 to 6 in the preparation of a drug for the treatment or auxiliary treatment of liver fibrosis.

9. Use of the lysosome-targeted chimera for dual-targeted protein degradation as described in any one of claims 1 to 6 in the preparation of a drug for treating or assisting in the treatment of diseases related to the degradation of PD-L1 and CD-47.

10. Use of the lysosome-targeted chimera for dual-targeted protein degradation as described in any one of claims 1 to 6 in degrading PD-L1 and CD-47.

Citation Information

Patent Citations

  • Lysosome targeting chimera as well as preparation method and application thereof

    CN117122690A

  • LYTAC molecule modified by retinoic acid as well as preparation method and application of LYTAC molecule

    CN114522244A

Cited By

  • Anti-inflammatory chimera, reprogramming macrophage, preparation method and application

    CN120209162A